Org 3770 versus amitriptyline: A 6‐week randomized double‐blind multicentre trial in hospitalized depressed patients
Authors:
- 1 May 1995
- journal article
- research article
- Published by Wiley in Human Psychopharmacology: Clinical and Experimental
- Vol. 10 (3) , 173-180
Abstract
Following a placebo washout period of 3–7 days, 251 hospitalized patients with a major depressive episode (DSM III and RDC criteria) were treated with either Org 3770 (20–60 mg/day) or amitriptyline (75–225 mg/day) for six consecutive weeks in this randomized, double‐blind, multicentre study. Forty‐one patients (19 Org 3770, 22 amitriptyline) withdrew before completion of the 6‐week active treatment period. In both groups, the main reason for withdrawal was lack of efficacy. However, fewer patients in the Org 3770 group than in the amitriptyline group withdrew as a result of adverse events (one and three patients, respectively). The severity of depressive symptoms and general psychopathology, as assessed by HPRSD (total and factors) and BPRS scales, improved to the same extent after 6 weeks' treatment with Org 3770 and amitriptyline. Similar improvement in global functioning, as assessed by GAS scale, was observed in both treatment groups. There were no statistically significant differences between the two treatments on all scales used. Dry mouth and sweating were reported significantly more often in the amitriptyline group. Other adverse events, such as constipation, dizziness, tremor and muscle weakness, occurred more frequently in the amitriptyline‐treated patients as well. The results of this study indicate that Org 3770 has similar antidepressant efficacy to amitriptyline and a more favourable tolerability profile in patients with major depression.Keywords
This publication has 17 references indexed in Scilit:
- The α2-adrenoceptor antagonist Org 3770 enhances serotonin transmission in vivoEuropean Journal of Pharmacology, 1994
- Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdosesThe Lancet, 1993
- Possible Monoamine Oxidase Inhibitor-Serotonin Uptake Inhibitor InteractionJournal of Clinical Psychopharmacology, 1993
- Treatments of Depression and the Functional Capacity to WorkArchives of General Psychiatry, 1992
- The effect of adrenergic drugs on serotonin metabolism in the nucleus raphe dorsalis of the rat, studied by in vivo voltammetryEuropean Journal of Pharmacology, 1992
- Edinburgh primary care depression study: treatment outcome, patient satisfaction, and cost after 16 weeks.BMJ, 1992
- REMERGON EFFICACY IN MAJOR DEPRESSIVE EPISODE: A RANDOMIZED, DOUBLE-BLIND, CLOMIPRAMINE-CONTROLLED STUDY IN 174 FRENCH HOSPITALIZED PATIENTS.Clinical Neuropharmacology, 1992
- The Safety of AntidepressantsDrugs, 1992
- Fatal toxicity of antidepressant drugs in overdose.BMJ, 1987
- The Diagnosis of Depressive Syndromes and the Prediction of E.C.T. ResponseThe British Journal of Psychiatry, 1965